225 related articles for article (PubMed ID: 32449862)
1. YAP confers resistance to vandetanib in medullary thyroid cancer.
Wang H; Tang J; Su Z
Biochem Cell Biol; 2020 Jun; 98(3):443-448. PubMed ID: 32449862
[TBL] [Abstract][Full Text] [Related]
2. Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.
Starenki D; Hong SK; Wu PK; Park JI
Cancer Biol Ther; 2017 Jul; 18(7):473-483. PubMed ID: 28475408
[TBL] [Abstract][Full Text] [Related]
3. Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo.
Starenki D; Park JI
J Clin Endocrinol Metab; 2013 Apr; 98(4):1529-40. PubMed ID: 23509102
[TBL] [Abstract][Full Text] [Related]
4. Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.
Kumarasamy VM; Sun D
Int J Oncol; 2017 Jul; 51(1):145-157. PubMed ID: 28498409
[TBL] [Abstract][Full Text] [Related]
5. Vandetanib therapy in medullary thyroid cancer.
Grabowski P; Briest F; Baum RP; Zaknun JJ; Kulkarni HR; Zeitz M; Hörsch D
Drugs Today (Barc); 2012 Nov; 48(11):723-33. PubMed ID: 23170308
[TBL] [Abstract][Full Text] [Related]
6. Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice.
Starenki D; Singh NK; Jensen DR; Peterson FC; Park JI
Cancer Lett; 2013 Oct; 339(1):144-51. PubMed ID: 23856028
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
Del Rivero J; Edgerly M; Ward J; Madan RA; Balasubramaniam S; Fojo T; Gramza AW
Oncologist; 2019 Jan; 24(1):16-e14. PubMed ID: 30297385
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
[TBL] [Abstract][Full Text] [Related]
9. Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by reverse phase protein array.
Broutin S; Commo F; De Koning L; Marty-Prouvost B; Lacroix L; Talbot M; Caillou B; Dubois T; Ryan AJ; Dupuy C; Schlumberger M; Bidart JM
Thyroid; 2014 Jan; 24(1):43-51. PubMed ID: 24256343
[TBL] [Abstract][Full Text] [Related]
10. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.
Vitagliano D; De Falco V; Tamburrino A; Coluzzi S; Troncone G; Chiappetta G; Ciardiello F; Tortora G; Fagin JA; Ryan AJ; Carlomagno F; Santoro M
Endocr Relat Cancer; 2011 Feb; 18(1):1-11. PubMed ID: 20943719
[TBL] [Abstract][Full Text] [Related]
11. Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation.
Giardino E; Catalano R; Barbieri AM; Treppiedi D; Mangili F; Spada A; Arosio M; Mantovani G; Peverelli E
Mol Cell Endocrinol; 2019 Sep; 495():110519. PubMed ID: 31352037
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib.
Lassalle S; Zangari J; Popa A; Ilie M; Hofman V; Long E; Patey M; Tissier F; Belléannée G; Trouette H; Catargi B; Peyrottes I; Sadoul JL; Bordone O; Bonnetaud C; Butori C; Bozec A; Guevara N; Santini J; Hénaoui IS; Lemaire G; Blanck O; Vielh P; Barbry P; Mari B; Brest P; Hofman P
Oncotarget; 2016 May; 7(21):30461-78. PubMed ID: 27036030
[TBL] [Abstract][Full Text] [Related]
13. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.
Johanson V; Ahlman H; Bernhardt P; Jansson S; Kölby L; Persson F; Stenman G; Swärd C; Wängberg B; Stridsberg M; Nilsson O
Endocr Relat Cancer; 2007 Jun; 14(2):433-44. PubMed ID: 17639056
[TBL] [Abstract][Full Text] [Related]
14. Selective use of vandetanib in the treatment of thyroid cancer.
Fallahi P; Di Bari F; Ferrari SM; Spisni R; Materazzi G; Miccoli P; Benvenga S; Antonelli A
Drug Des Devel Ther; 2015; 9():3459-70. PubMed ID: 26170630
[TBL] [Abstract][Full Text] [Related]
15. Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both
Demir Gündoğan B; Sağcan F; Tuğ Bozdoğan S; Balcı Y; Tuncel Daloğlu F; Çağlar Çıtak E
J Clin Res Pediatr Endocrinol; 2021 Aug; 13(3):342-346. PubMed ID: 32702947
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
17. The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.
Verbeek HH; Alves MM; de Groot JW; Osinga J; Plukker JT; Links TP; Hofstra RM
J Clin Endocrinol Metab; 2011 Jun; 96(6):E991-5. PubMed ID: 21470995
[TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
Fallahi P; Ferrari SM; Baldini E; Biricotti M; Ulisse S; Materazzi G; Miccoli P; Antonelli A
Expert Rev Anticancer Ther; 2016 Nov; 16(11):1109-1118. PubMed ID: 27650489
[TBL] [Abstract][Full Text] [Related]
19. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M
J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189
[TBL] [Abstract][Full Text] [Related]
20. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
[Next] [New Search]
